Arvelle Therapeutics Licenses Exclusive Development & Commercialization Rights for Cenobamate from SK Biopharmaceuticals in EU

Shots:

• SK Biopharmaceuticals to receive $100M upfront, $430M milestones, and royalties on sales of product. Arvelle to get exclusive rights to develop and commercialize SK’s Cenobamate in EU
• SK also has an option to make equity investment in Arvelle and will retain WW commercialization rights for Cenobamate (Ex-EU). Arvelle plans to file Cenobamate’s MAA to EU based on the trial conducted by SK, for partial-onset seizures in adults 
• Cenobamate (YKP3089) is an antiepileptic drug involved in modulating GABA-A receptor and has received NDA approval from the US FDA for partial-onset seizures in adults in Feb, 2019

Click here to read full press release/ article | Ref: GlobeNewwire | Image:  Twitter